8-K: Immix Biopharma Establishes $50 Million At-The-Market Equity Offering Program

Immix Biopharma, Inc. has entered into an At The Market Offering Agreement with Citizens JMP Securities, LLC to potentially sell up to $50 million of its common stock, providing a flexible capital raising mechanism.

Summary

• Immix Biopharma, Inc. (the "Company") has entered into an At The Market Offering Agreement (the "Agreement") with Citizens JMP Securities, LLC (the "Agent") on June 3, 2025.
• Under the Agreement, the Company may offer and sell, from time to time at its sole discretion, shares of its common stock with an aggregate offering price of up to $50,000,000.
• Sales will be made through the Agent as its sales agent, utilizing methods defined as "at the market offering" under Rule 415(a)(4) of the Securities Act, including privately negotiated and block transactions.
• The Company will pay the Agent a commission of 3% of the gross sales proceeds from any common stock sold under the Agreement.
• The Company will also reimburse the Agent for certain specified expenses up to a maximum of $50,000.
• The offering will be made under the Company's effective Registration Statement on Form S-3 (File No. 333-269100), which became effective on January 11, 2023, and a prospectus supplement filed on June 3, 2025.

Sentiment

Score: 6

Explanation: The establishment of an At The Market offering provides a crucial and flexible funding mechanism for Immix Biopharma, which is positive for its operational continuity and strategic planning. However, it also introduces potential future dilution for existing shareholders, balancing the overall sentiment to moderately positive.

Positives

• Provides a flexible and efficient mechanism for Immix Biopharma to raise capital as needed, without the immediate dilution or pricing pressure of a single large offering.
• Allows the Company to access capital over time, potentially aligning with its funding requirements for ongoing operations and research and development.
• The "at the market" structure can minimize market impact compared to traditional underwritten offerings, as shares are sold into the open market at prevailing prices.

Negatives

• Potential for dilution of existing shareholders as new shares are issued into the market.
• The timing and amount of share sales are at the Company's discretion, which can create uncertainty for investors regarding future share supply.
• The 3% commission to the Agent and up to $50,000 in expense reimbursements will reduce the net proceeds received by the Company.

Risks

• Market Conditions: The Company's ability to raise the full $50 million is dependent on favorable market conditions and its stock price performance.
• Share Price Volatility: Future sales under the ATM program could put downward pressure on the Company's stock price due to increased supply.
• Dilution: Issuance of new shares will dilute the ownership percentage of current shareholders.
• Uncertainty of Proceeds: There is no guarantee that the Company will be able to sell the full $50 million worth of shares or at what average price.

Future Outlook

The At The Market Offering Agreement provides Immix Biopharma with a flexible financing tool to raise capital as needed for general corporate purposes, which typically includes funding ongoing operations, research and development, and potential strategic initiatives. The Company will apply the net proceeds from the sale of shares in the manner set forth in the Prospectus.

Industry Context

At-the-market (ATM) offerings are a common and flexible capital-raising strategy for biopharmaceutical companies, particularly those in clinical development stages that require continuous funding for research, clinical trials, and operational expenses without immediate product revenue. This mechanism allows companies like Immix Biopharma to access capital incrementally, adapting to market conditions and specific funding needs, which is crucial given the long and capital-intensive nature of drug development.

Comparison to Industry Standards

• The use of an At-The-Market (ATM) offering is a standard financing tool for publicly traded biopharmaceutical companies, especially those with ongoing R&D needs and no consistent revenue streams.
• The 3% commission rate for the sales agent is within the typical range for ATM agreements in the industry, which often fall between 1% and 3.5%.
• The maximum offering size of $50 million is a common amount for such programs, providing a significant but not overwhelming capital runway for a company of Immix Biopharma's likely stage.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for dilution of existing shareholdings as new shares are issued. Provides the company with capital to fund operations, which could support long-term value if successful.
• Company Operations: Secures a flexible funding source to support ongoing research and development, clinical trials, and general corporate expenses.

Next Steps

• Immix Biopharma may, at its sole discretion, offer and sell shares of its common stock through Citizens JMP Securities, LLC under the Agreement.
• The Company will continue to comply with SEC reporting requirements, including disclosing sales under the ATM program in its periodic reports.

Key Dates

Keywords

Immix Biopharma, IMMX, At The Market Offering, ATM, Equity Offering, Capital Raise, Common Stock, SEC Filing, Form 8-K, Dilution, Biopharma, Financing